Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer

Future Oncology

Volumn 9, Issue 6, 2013, Pages 889-897

  Buonerba, Carlo ^a   Pond, Gregory R ^b   Sonpavde, Guru ^c   Federico, Piera ^a   Rescigno, Pasquale ^a   Puglia, Livio ^a   Bosso, Davide ^a   Virtuoso, Antonella ^a   Policastro, Tania ^a   Izzo, Michela ^a   Vaccaro, Luca ^a   Ferro, Matteo ^a   Aieta, Michele ^d   Perdonà, Sisto ^e   Palmieri, Giovannella ^a   De Placido, Sabino ^a   Di Lorenzo, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UO Oncologia Ospedale Oncologico Regionale   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

cabazitaxel; Gleason score; prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COMPASSIONATE USE; DIAGNOSTIC VALUE; DRUG EFFICACY; GLEASON SCORE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; CASTRATION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84878474105     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.39     Document Type: Article

References (25)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
3. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer 46 (17), 3040-3052 (2010).
4. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 70(8), 983-1000 (2010).
5. Buonerba C, Palmieri G, Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: scientifc legitimacy of common clinical practice. Eur. Urol. 58(4), 636-637 (2010).
6. Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr. Drug Targets 13(13), 1676-1686 (2012).
7. Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev. Anticancer Ther. 11(1) 5-28 (2011).
8. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 10(5), 117-124 (2011).
9. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154 (2010).
10. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
11. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
12. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 61, 549-559 (2012).
13. Azria D, Massard C, Tosi D et al. An ambispective observational study in the safety and effcacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. J. Clin. Oncol. 30(Suppl. 5), Abstract 149 (2012).
14. Di Lorenzo G, DAniello C, Buonerba C et al. Peg-flgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24(1), 84-89 (2013).
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
16. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1, 277-299 (1975).
17. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 29(9), 1228-1242 (2005).
18. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21, 1232-1237 (2003).
19. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study ana lysis. Clin. Cancer Res. 13(21), 6396-6403 (2007).
20. Ryan C, Li J, Kheoh T, Scher HI, Molina A. Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 Phase 3 randomized trial. Cancer Res. 72(8 Suppl. 1), Abstract LB-434 (2012).
21. Ryan C, Peng W, Kheoh T, Scher HI, Molina A. Association of reduction in serum androgens and change in serum PSA in patients treated with abiraterone acetate (AA): a subset ana lysis of the COU-AA-301 Phase 3 randomized trial. Cancer Res. 72(8 Suppl. 1), Abstract 3635 (2012).
22. Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30(6), 637-643 (2012).
23. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69(7), 2912-2918 (2009).
24. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following frst-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 16(1), 203-211 (2010).
25. Heidenreich A, Scholz HJ, Rogenhofer S et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur. Urol. 63(6), 977-982 (2013).